当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

Abstract：

:Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead to the production of high levels of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). Here we report the characterization of BAY1436032, a novel pan-mutant IDH1 inhibitor, both in vitro and in vivo. BAY1436032 specifically inhibits R-2HG production and colony growth, and induces myeloid differentiation of AML cells carrying IDH1R132H, IDH1R132C, IDH1R132G, IDH1R132L and IDH1R132S mutations. In addition, the compound impacts on DNA methylation and attenuates histone hypermethylation. Oral administration of BAY1436032 led to leukemic blast clearance, myeloid differentiation, depletion of leukemic stem cells and prolonged survival in two independent patient-derived xenograft IDH1 mutant AML mouse models. Together, BAY1436032 is highly effective against all major types of IDH1 mutant AML.

journal_name

Leukemia

journal_title

Leukemia

authors

Chaturvedi A,Herbst L,Pusch S,Klett L,Goparaju R,Stichel D,Kaulfuss S,Panknin O,Zimmermann K,Toschi L,Neuhaus R,Haegebarth A,Rehwinkel H,Hess-Stumpp H,Bauser M,Bochtler T,Struys EA,Sharma A,Bakkali A,Geffers R,Ara

doi

10.1038/leu.2017.46

subject

Has Abstract

pub_date

2017-10-01 00:00:00

pages

2020-2028

issue

10

eissn

0887-6924

issn

1476-5551

pii

leu201746

journal_volume

31

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Interleukin-6 autoantibodies: possible biological and clinical significance.

    abstract：:The pleiotropic cytokines, interleukin (IL)-1 alpha, type I interferons and IL-6 also act on cells involved in antibody production. Somehow the immunologic tolerance to these cytokines is often spontaneously broken--even in healthy individuals. Thus, relatively high concentrations of high affinity IgG antibodies again...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Hansen MB,Svenson M,Diamant M,Abell K,Bendtzen K

    更新日期：1995-07-01 00:00:00

  • Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.

    abstract：:Since graft-versus-leukemia (GVL) is the main weapon for disease eradication after reduced intensity conditioning (RIC) allogeneic SCT, the availability of sensitive and specific techniques to monitor changes in tumor load after transplant are especially helpful. These minimal residual disease techniques would allow a...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2402550

    authors： Pérez-Simón JA,Caballero D,Diez-Campelo M,Lopez-Pérez R,Mateos G,Cañizo C,Vazquez L,Vidriales B,Mateos MV,Gonzalez M,San Miguel JF

    更新日期：2002-08-01 00:00:00

  • Establishment and characterization of a new erythropoietin-dependent acute myeloid leukemia cell line, AS-E2.

    abstract：:We have established an erythropoietin-dependent human leukemia cell line, AS-E2, from a patient with acute myeloid leukemia. These cells have many characteristics of late erythroid progenitor cells, they are positive for CD36, Glycophorin A, and CD71 but negative for CD41, and positive for benzidine and PAS staining. ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400838

    authors： Miyazaki Y,Kuriyama K,Higuchi M,Tsushima H,Sohda H,Imai N,Saito M,Kondo T,Tomonaga M

    更新日期：1997-11-01 00:00:00

  • BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Ev

    abstract：:The flow cytometric detection of minimal residual disease (MRD) in precursor-B-acute lymphoblastic leukemias (precursor-B-ALL) mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. Th...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402150

    authors： Lucio P,Gaipa G,van Lochem EG,van Wering ER,Porwit-MacDonald A,Faria T,Bjorklund E,Biondi A,van den Beemd MW,Baars E,Vidriales B,Parreira A,van Dongen JJ,San Miguel JF,Orfao A,BIOMED-I.

    更新日期：2001-08-01 00:00:00

  • Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.

    abstract：:The presence of CD19 in myelomatous plasma cells (MM-PCs) correlates with adverse prognosis in multiple myeloma (MM). Although CD19 expression is upregulated by CD81, this marker has been poorly investigated and its prognostic value in MM remains unknown. We have analyzed CD81 expression by multiparameter flow cytomet...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.42

    authors： Paiva B,Gutiérrez NC,Chen X,Vídriales MB,Montalbán MÁ,Rosiñol L,Oriol A,Martínez-López J,Mateos MV,López-Corral L,Díaz-Rodríguez E,Pérez JJ,Fernández-Redondo E,de Arriba F,Palomera L,Bengoechea E,Terol MJ,de Paz R,Mar

    更新日期：2012-08-01 00:00:00

  • Treatment of resistant disease.

    abstract：:Resistant AML encompasses two groups of patients: those with refractory leukemia and those whose leukemia has relapsed. Refractory leukemia is disease that does not respond to initial induction chemotherapy with cytarabine and an anthracycline. Patients with refractory leukemia are likely to have disease with adverse ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Schiller GJ

    更新日期：1998-09-01 00:00:00

  • Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75).

    abstract：:The lens epithelium-derived growth factor (LEDGF/p75) tethers the mixed-lineage leukemia (MLL1) protein complex to chromatin. Likewise, LEDGF/p75 tethers the HIV-1 pre-integration complex to chromatin. We previously demonstrated that expression of the C-terminal fragment fused to enhanced green fluorescent protein (eG...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.10

    authors： Méreau H,De Rijck J,Cermáková K,Kutz A,Juge S,Demeulemeester J,Gijsbers R,Christ F,Debyser Z,Schwaller J

    更新日期：2013-06-01 00:00:00

  • Abnormalities of chromosome 16q in myeloid malignancy: 14 new cases and a review of the literature.

    abstract：:Fourteen patients with abnormalities of chromosome 16q, 13 with acute myelogenous leukaemia (AML), and one with refractory anaemia with excess of blasts (RAEB), are described. Seven patients had inv(16)(p13q22), two had del(16)(q22), and five had other abnormalities of 16q. Six of the seven patients with inv(16) had A...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：

    authors： Betts DR,Rohatiner AZ,Evans ML,Rassam SM,Lister TA,Gibbons B

    更新日期：1992-12-01 00:00:00

  • Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant.

    abstract：:Retroviral gene transfer into hematopoietic cells has many experimental as well as clinical applications. Although transduction efficiency of retroviral vectors is higher than with conventional methods, selection of successfully transduced cells may become mandatory for efficient in vivo transfer. We have been evaluat...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Flasshove M,Banerjee D,Bertino JR,Moore MA

    更新日期：1995-10-01 00:00:00

  • Haplotype study of microsatellites flanking the t(15;17) breakpoint in acute promyelocytic leukemia patients from North Portugal.

    abstract：:A higher frequency of acute promyelocytic leukemia (APL) has been noted in countries of Southern Europe and among 'Latino' patients of the United States with acute myeloid leukemia (AML). In order to discover whether there is any genetic predisposition to the disease, we analyzed microsatellites flanking PML and RARal...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402525

    authors： Martins S,Trigo F,Azevedo L,Silva MJ,Guimaraes JE,Amorim A

    更新日期：2002-07-01 00:00:00

  • A case of acute megakaryocytic leukemia with hematogones.

    abstract：:A case of an infant male with Down's syndrome, pancytopenia, and a relative lymphocytosis is presented. A bone marrow aspirate and crushed marrow biopsy were evaluated by microscopy and flow cytometry. A population of immature lymphoid cells positive for CD10 (CALLA) and CD19 (Leu 12) was initially interpreted as sugg...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Richard G,Brody J,Sun T

    更新日期：1993-11-01 00:00:00

  • The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation.

    abstract：:Hematopoietic stem cell transplantation is becoming an increasingly important approach to treatment of different malignant and non-malignant disorders. There is thus growing demand for diagnostic assays permitting the surveillance of donor/recipient chimerism posttransplant. Current techniques are heterogeneous, rende...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.66

    authors： Lion T,Watzinger F,Preuner S,Kreyenberg H,Tilanus M,de Weger R,van Loon J,de Vries L,Cavé H,Acquaviva C,Lawler M,Crampe M,Serra A,Saglio B,Colnaghi F,Biondi A,van Dongen JJ,van der Burg M,Gonzalez M,Alcoceba M,Bar

    更新日期：2012-08-01 00:00:00

  • Improved detection of minimal residual leukemia through modifications of polymerase chain reaction analyses based on clonospecific T cell receptor junctions.

    abstract：:Polymerase chain reaction (PCR) techniques utilizing clonospecific T cell receptor (TCR) gamma or delta junctional regions constitute broadly applicable strategies to study the clinical relevance of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) patients. For the majority of cases current PCR pro...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：

    authors： Seriu T,Hansen-Hagge TE,Erz DH,Bartram CR

    更新日期：1995-02-01 00:00:00

  • Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.

    abstract：:Hemizygous deletions are common molecular abnormalities in cancer. In some cases, these deletions highlight chromosomal loci containing tumor suppressor genes that undergo homozygous inactivation. In other cases, hemizygous deletions cause disease by allelic insufficiency for one or more genes. As the intact allele ha...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2009.53

    authors： Ebert BL

    更新日期：2009-07-01 00:00:00

  • Effect of hyperthermia on both primary proliferation and self-renewal of human leukemic progenitor cells in vitro: its application to in vitro purging.

    abstract：:Self-renewal, as defined by the capacity to yield new colonies following replating, is an important function of leukemic progenitors (L-CFU) to originate self-maintaining clones. In this work, we studied the effect of hyperthermia (41-44 degrees C) on the growth of human L-CFU derived primary colonies and of secondary...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Moriyama Y,Nikkuni K,Saito H,Aoki A,Kishi K,Takahashi M,Shibata A

    更新日期：1991-04-01 00:00:00

  • Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

    abstract：:This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1-4...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.173

    authors： Richardson PG,Hofmeister CC,Raje NS,Siegel DS,Lonial S,Laubach J,Efebera YA,Vesole DH,Nooka AK,Rosenblatt J,Doss D,Zaki MH,Bensmaine A,Herring J,Li Y,Watkins L,Chen MS,Anderson KC

    更新日期：2017-12-01 00:00:00

  • Characterization of the immunoglobulin light chain variable region gene expressed in multiple myeloma.

    abstract：:We studied the organization, diversification and clinical significance of the immunoglobulin light chain (IgL) variable region genes expressed in 17 kappa-chain and 16 lambda-chain producing multiple myeloma (MM) samples. The V genes from 31 MM samples had over 84.9% homology to the known germline Vkappa/lambda genes,...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400972

    authors： Kiyoi H,Naito K,Ohno R,Saito H,Naoe T

    更新日期：1998-04-01 00:00:00

  • Expression of the LH2 gene in chronic myeloid leukaemia cells.

    abstract：:The LH2 gene encodes a putative transcription factor containing two N-terminal LIM and one C-terminal HOX domains. The LH2 locus was mapped to 9q33-34.1, centromeric to the ABL gene. In a recent report, it was suggested that high levels of LH2 expression are consistently observed in chronic myeloid leukemia (CML) pati...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Al-Jehani F,Hochhaus A,Spencer A,Goldman JM,Melo JV

    更新日期：1996-07-01 00:00:00

  • A new retroviral AIDS-like disease and/or acute leukemia induced in mice by alloimmune stimuli.

    abstract：:We have shown a new phenomenon demonstrating that BALB/c female mice mated to C57BL/6 males during a year (7-10 pregnancies) develop AIDS-like disease or acute leukemia after an additional immunization with fixed ConA activated paternal (C57BL/6) lymphocytes. The AIDS-like disease is sexually and vertically transmissi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Ter-Grigorov V,Krifuks O,Liubashevsky E,Nyska A,Toder V,Trainin Z

    更新日期：1997-04-01 00:00:00

  • Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia.

    abstract：:Donor leukocyte infusions (DLI) have turned out to be an efficient way to re-establish complete remission (CR) in chronic myeloid leukemia (CML) patients relapsing after allogeneic bone marrow transplantation (BMT). In these patients, absence of PCR bcr-abl fusion transcripts confirmed the potency of donor leukocytes ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401144

    authors： Berthou C,Léglise MC,Herry A,Balcon D,Hardy E,Lessard M,Abgrall JF

    更新日期：1998-11-01 00:00:00

  • Induction of centrosome and chromosome aberrations by imatinib in vitro.

    abstract：:Imatinib (STI571, Gleevec/Glivec) is a potent selective tyrosine kinase inhibitor and is used successfully in the treatment of chronic myeloid leukemia (CML). While karyotype alterations, in addition to the Philadelphia chromosome, are a common phenomenon of progressing CML, the observation of BCR-ABL-negative leukemi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403861

    authors： Fabarius A,Giehl M,Frank O,Duesberg P,Hochhaus A,Hehlmann R,Seifarth W

    更新日期：2005-09-01 00:00:00

  • Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

    abstract：:Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a ...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/leu.2016.299

    authors： Schlenk RF,Stegelmann F,Reiter A,Jost E,Gattermann N,Hebart H,Waller C,Hochhaus A,Platzbecker U,Schafhausen P,Blau IW,Verbeek W,Heidel FH,Werner M,Kreipe H,Teleanu V,Benner A,Döhner H,Grießhammer M,Döhner K

    更新日期：2017-04-01 00:00:00

  • Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.

    abstract：:We have analysed the structure of the T-cell receptor gamma chain (TCRG) genes in a panel of biopsies taken from 24 patients with acute lymphoblastic leukemia (ALL) (13 cALL, one pre-B ALL, two null ALL and eight T-ALL) at presentation and at clinical relapse. In the majority of cases (18/24) the structure of these ge...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Taylor JJ,Rowe D,Kylefjord H,Chessells J,Katz F,Proctor SJ,Middleton PG

    更新日期：1994-01-01 00:00:00

  • Studies of decitabine with allogeneic progenitor cell transplantation.

    abstract：:The aim was to determine the efficacy and safety of decitabine in the settings of relapse post-allogeneic progenitor cell transplantation or as part of the conditioning regimen. Three patients (two AML, one ALL) received single agent decitabine 1000 mg/m2 total dose) for treatment of relapse post-transplant (group 1)....

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：

    authors： Giralt S,Davis M,O'Brien S,van Besien K,Champlin R,de Vos D,Kantarjian H

    更新日期：1997-03-01 00:00:00

  • A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.

    abstract：:A phase III clinical trial was developed to test whether the addition of etoposide to a high-dose cytosine arabinoside regimen would improve the remission rate, duration of remission, and survival in relapsed and refractory patients with acute myelogenous leukemia. One hundred and thirty-one patients stratified by age...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Vogler WR,McCarley DL,Stagg M,Bartolucci AA,Moore J,Martelo O,Omura GA

    更新日期：1994-11-01 00:00:00

  • Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

    abstract：:Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detecti...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.leu.2404586

    authors： van der Velden VH,Cazzaniga G,Schrauder A,Hancock J,Bader P,Panzer-Grumayer ER,Flohr T,Sutton R,Cave H,Madsen HO,Cayuela JM,Trka J,Eckert C,Foroni L,Zur Stadt U,Beldjord K,Raff T,van der Schoot CE,van Dongen JJ,Euro

    更新日期：2007-04-01 00:00:00

  • Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

    abstract：:We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III-IV organ damage, engraftment fail...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2405014

    authors： de Lima M,Champlin RE,Thall PF,Wang X,Martin TG 3rd,Cook JD,McCormick G,Qazilbash M,Kebriaei P,Couriel D,Shpall EJ,Khouri I,Anderlini P,Hosing C,Chan KW,Andersson BS,Patah PA,Caldera Z,Jabbour E,Giralt S

    更新日期：2008-02-01 00:00:00

  • Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.

    abstract：:We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 genes performed in 330 patients included in this trial, 163 patients bein...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-01031-1

    authors： Largeaud L,Cornillet-Lefebvre P,Hamel JF,Dumas PY,Prade N,Dufrechou S,Plenecassagnes J,Luquet I,Blanchet O,Banos A,Béné MC,Bernard M,Bertoli S,Bonmati C,Fornecker LM,Guièze R,Haddaoui L,Hunault M,Ianotto JC,Jourdan

    更新日期：2020-09-18 00:00:00

  • Tissue factor and plasminogen activator inhibitor expression in the differentiation of myeloid leukemic cells.

    abstract：:Disturbances in the regulation of the balance between the fibrinolytic and procoagulant properties of leukemic cells may contribute to the coagulopathy of acute leukemia. The coagulant response to a number of stimuli is regulated by the expression of tissue factor, but the role of the plasminogen activator inhibitors,...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Dickinson JL,Antalis TM

    更新日期：1993-06-01 00:00:00

  • The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia.

    abstract：:The oncogene kit has been shown genetically to map in the W locus of the mouse. This locus is known to have an important role in the regulation of normal hemopoietic stem cell growth. The blast cells of acute myeloblastic leukemia may be considered to arise in predeterministic stem cells. Accordingly, we sought eviden...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Wang C,Curtis JE,Geissler EN,McCulloch EA,Minden MD

    更新日期：1989-10-01 00:00:00